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SUMMARY – Th e aim of this study was to demonstrate epidemiological, clinical and endo-
scopic characteristics of acute upper gastrointestinal bleeding (UGIB) with special reference to peptic 
ulcer bleeding (PUB). Th e study included 2198 consecutive patients referred to our emergency depart-
ment due to acute UGIB from January 2008 to December 2012. All patients underwent urgent upper 
GI endoscopy within 24 hours of admission, and 842 patients diagnosed with PUB were enrolled and 
prospectively followed-up. Th e cumulative incidence of UGIB was 126/100,000 in the 5-year period. 
Two out of fi ve patients had a bleeding peptic ulcer; in total, 440 (52.3%) had bleeding gastric ulcer, 
356 (42.3%) had bleeding duodenal ulcer, 17 (2%) had both bleeding gastric and duodenal ulcers, and 
29 (3.5%) patients had bleeding ulcers on gastroenteric anastomoses. PUB was more common in men. 
Th e mean patient age was 65.9 years. Th e majority of patients (57%) with PUB were taking agents that 
attenuate the cytoprotective function of gastric and duodenal mucosa. Rebleeding occurred in 77 
(9.7%) patients and 47 (5.9%) patients required surgical intervention. Th e 30-day morality was 5.2% 
and 10% of patients died from uncontrolled bleeding and concomitant diseases. In conclusion, PUB 
is the main cause of UGIB, characterized by a signifi cant rebleeding rate and mortality.
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Introduction
Upper gastrointestinal bleeding (UGIB) is a com-
mon medical emergency and accounts for 5% of emer-
gency department presentations per year and 2% to 3% 
of hospital admissions in developed countries1. Th e 
incidence rate of UGIB varies from 48 to 160 cases per 
100,000 population, with consistent reports of higher 
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incidence among men and the elderly2. Th e most com-
mon cause of acute UGIB is non-variceal, where pep-
tic ulcer bleeding (PUB) accounts for 28% to 59% of 
cases2-4.
Endoscopy has become the standard of care in the 
diagnosis and treatment of UGIB. Most national and 
international guidelines recommend performing upper 
endoscopy within 24 hours of presentation in patients 
with UGIB5-7. Despite major advances in diagnostic 
and therapeutic approaches, PUB remains a signifi cant 
problem and an important cause of morbidity and 
mortality. Rebleeding after initial hemostasis occurs in 
10% to 30% of patients with PUB8-11. Th e reported 
PUB mortality rates in various countries across Eu-
rope range from 3.4% to 14%, and the reason for this 
diff erence remains unknown12-15.
Th e aim of this prospective study was to determine 
the epidemiological, clinical and endoscopic charac-
teristics of UGIB with a focus on the treatment and 
prognosis of PUB in a tertiary care center. 
Patients and Methods
Th is prospective study was conducted in a tertiary 
care center in the City of Zagreb, Croatia, which cov-
ers a population of approximately 300,000 people. All 
consecutive patients presenting with UGIB (he-
matemesis, melena, hematochezia or blood admixture 
upon nasogastric aspiration) to the Emergency Inter-
nal Medicine Unit, Sestre milosrdnice University 
Hospital Center between January 2008 and December 
2012 were included. Th ese patients were then, if neces-
sary, hospitalized in the Interventional Gastroenterol-
ogy Unit of the same hospital. If the same patient was 
hospitalized more than once during the study period, 
only the fi rst episode was counted as the incident case, 
irrespective of previous or subsequent episodes of PUB.
Upper gastrointestinal endoscopy was performed 
in all patients within 24 hours of hospital admission. 
Only patients with PUB confi rmed by endoscopy were 
prospectively followed-up for 30 days. After initial en-
doscopic examination, patients in whom endoscopic 
therapy had been performed were hospitalized. All pa-
tients received high-dose acid suppression therapy 
(pantoprazole or esomeprazole 80 mg intravenously as 
an initial bolus followed by 40 mg intravenously and/
or oral 3 times per day for at least 48 hours, followed by 
40 mg daily per os).
Prior to endoscopy, a written informed consent was 
obtained from all patients or their relatives, which in-
cluded possible risks, benefi ts and treatment options 
during the procedure. In addition, a written informed 
consent was obtained from patients or their relatives 
before trial entry. Th e study was approved by the Eth-
ics Committee of the hospital. Data were collected 
prospectively into a database, with patient details 
stored in a depersonalized manner to protect patient 
confi dentiality.
Data collection
Th e following data were collected for each patient: 
demographic data, signs and characteristics of the 
bleeding episode, symptoms and history of ulcer or 
liver disease, coexisting illness, drug use, laboratory re-
sults, endoscopic diagnosis including the cause of 
bleeding, presence of fresh blood/clots or stigmata of 
recent hemorrhage, endoscopic intervention, medical 
treatment, rebleeding incidence, surgical therapy, du-
ration of hospitalization and cause of death. Shock was 
defi ned as syncope or signs of shock upon physical ex-
amination, including systolic blood pressure <100 mm 
Hg or heart rate >100 beats/min.
Grading of overall health and comorbidity was 
performed according to the American Society of An-
esthesiology (ASA) classifi cation (grade 1, normal 
healthy patients; grade 2, mild systemic illness; grade 
3, severe, but incapacitating systemic illness; and grade 
4, life-threatening illness). Stigmata of recent hemor-
rhage were defi ned according to Forrest classifi cation 
as follows: Forrest Ia, spurting bleeding; Forrest Ib, 
oozing bleeding; Forrest IIa, non-bleeding visible ves-
sel; Forrest IIb, adherent clot; Forrest IIc, hematin on 
ulcer base; and Forrest III, clean ulcer base16. Th e size 
of ulcer was classifi ed as <2 cm or ≥2 cm. Th e com-
monly used hemostatic procedures were epinephrine 
injections (1:10000 solution of epinephrine) and/or 
mechanical hemostasis with stainless steel hemoclips 
(Olympus, Japan) and/or thermocoagulation with a 
heater probe (Olympus, 7F, 20-30 joules).
Two biopsy specimens were obtained from the gas-
tric antrum and body in all patients and the presence of 
Helicobacter pylori (H. pylori) infection was assessed by 
histopathologic examination of the specimens using 
hematoxylin-eosin (HE) stain. In all patients with gas-
tric ulcers in whom recurrent bleeding was not observed, 
follow-up endoscopy was performed four to fi ve days 
after initial hemostasis and biopsy specimens were ob-
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tained from the margins and base of gastric ulcers to 
exclude malignancy. Follow-up endoscopy with histol-
ogy was planned in all patients with gastric ulcers. In all 
patients with negative histology for H. pylori at index 
endoscopy, urea breath test (UBT) or follow-up endos-
copy with histology was performed 2 weeks after proton 
pump inhibitor (PPI) treatment had been discontinued. 
Patients were considered positive for H. pylori infection 
in case of positive histology or positive UBT.
Clinical outcomes of PUB were analyzed accord-
ing to the rebleeding rate, need for surgical interven-
tion, need for blood transfusion, length of hospital stay, 
and 30-day mortality.
Rebleeding was defi ned as one or more signs of on-
going bleeding, including fresh hematemesis or melena, 
hematochezia, aspiration of fresh blood via nasogastric 
tube, instability of vital signs, and reduction of hemo-
globin or hematocrit levels by more than 2 g/dL or 5%, 
respectively, over a 24-hour period after primary bleed-
ing was stopped. Patients that had unsuccessful initial 
endoscopic treatment or more than two successful re-
treatments underwent emergency surgery.
Statistics
All analyses were performed with the Statistica 
11.0 (Statsoft, Inc., Tulsa, OK) for Windows statistical 
package. Th e Mann-Whitney U-test and Kruskal-
Wallis ANOVA test were used as nonparametric tests 
where appropriate, and a p-value <0.05 was considered 
signifi cant. Th e predictive value of qualitative variables 
on mortality and rebleeding was studied in univariate 
analysis using Pearson χ2-test, when appropriate. Mul-
tivariate analysis was conducted using a forward elimi-
nation logistic regression model to identify a fi nal set 
of variables independently associated with either mor-
tality or rebleeding. A signifi cance level α=0.05 was 
used to retain variables in the multivariate model. All 
results were presented as odds ratios (ORs) with the 
associated 95% confi dence intervals (95% CIs). 
Results
From January 2008 to December 2012, 2198 pa-
tients with UGIB were analyzed; 89.5% of patients 
had non-variceal bleeding, 8.3% had variceal bleeding, 
and in 2.2% the source was not identifi ed.
In the group of patients with non-variceal bleed-
ing, 42.8% had bleeding ulcer, while 57.2% had non-
ulcer bleeding (Mallory-Weis tear, angiomata, Dieula-
foy’s lesion, malignancy, acute erosive gastropathy, re-
fl ux esophagitis, portal hypertensive gastropathy, arte-
rial enteric fi stula). In patients with bleeding ulcers, 
Fig. 1. Patients with upper gastrointestinal bleeding (UGIB) from 2008 to 2012.
I. Budimir et al. Bleeding peptic ulcer: epidemiology, treatment and prognosis
710 Acta Clin Croat, Vol. 56, No. 4, 2017
94.6% of cases were attributed to gastric or duodenal 
ulcers, 2% to both gastric and duodenal ulcers, and 
3.4% to ulcer on previous gastroenteric anastomoses 
(Fig. 1).
Th e cumulative incidence of UGIB in the observed 
5-year period was 126/100,000. In the group of 796 
patients that were carefully followed-up, 55.3% had 
bleeding from gastric ulcers and 44.7% from duodenal 
ulcers. Th e mean patient age was 65.9 years and men 
had a higher incidence of bleeding (62.9% vs. 37.1%; 
p<0.001). High risk ulcers (Forrest Ia-IIb) were veri-
fi ed in 52% of patients, most ulcers were >2 cm in di-
ameter, 9.7% of patients presented with shock, and 
57.9% of patients had moderate to severe comorbidi-
ties. When analyzed according to medication usage, 
28.3% of patients with peptic ulcers had been taking 
non-steroidal anti-infl ammatory drugs (NSAIDs), 
20.3% acetylsalicylic acid, 2.6% anti-aggregation med-
ication, 5.8% anti-coagulation therapy, and 9.2% gas-
troprotective medication (histamine 2 blockers or 
PPI). H. pylori testing was performed in 531 (66.7%) 
patients of which 220 (41.4%) tested positive. Th e 
presence of H. pylori infection was more common in 
patients with duodenal peptic ulcer (46.7% vs. 36.9%), 
which was statistically signifi cant (p<0.023) (Table 1).
Endoscopic treatment was performed in 456 
(58.4%) patients; in 54.3% of cases hemostasis was 
achieved with hemoclips or with a combination of he-
moclips and diluted epinephrine infi ltration. Rebleed-
ing occurred in 9.7% of patients (Table 2).
Th e risk of rebleeding was increased in patients 
with shock [OR 5.85 (CI 95% 3.01-11.37)], bleeding 
ulcer Forrest Ia type [OR 6.48 (CI 95% 3.12-13.48)] 
and ulcers >2 cm in diameter [OR 2.79 (CI 95% 1.49-
5.20)] (Fig. 2).
Forty-seven (5.9%) patients were transferred to the 
Department of Surgery (5 due to successful endoscop-







Gender (male/female), n (%) 501 (62.9)/295 (37.1)
Hb level median (range), g/L 93.9 (26-182)
Findings at endoscopy
Gastric ulcers 440 (55.3)
Duodenal ulcers 356 (44.7)
High-risk ulcers 
(Forrest Ia-IIb) 414 (52)
Low- risk ulcers 
(Forrest IIc-III) 382 (48)




Helicobacter pylori 220/531 (41.4)
Comorbidity (ASA class)
ASA I 110 (13.9)
ASA II 225 (28.2)
ASA III-IV 461 (57.9)
Medication
NSAIDs 225 (28.3)
Acetylsalicylic acid 162 (20.3)
Antiaggregation therapy 21 (2.6)
Anticoagulant therapy 46 (5.8)
Proton pump inhibitors 
or H2 blockers 73 (9.2)
Hb = hemoglobin; ASA = American Society of Anesthesiology; 
NSAIDs = nonsteroidal anti-infl ammatory drugs
Table 2. Endoscopic therapy and clinical outcomes
n (%)
Treatment
Endoscopic therapy 465 (58.4)
Initial hemostasis 411 (51.6)
Types of initial hemostasis
Epinephrine 164 (39.9)
Endoclips 81 (19.7)
Epinephrine + endoclips 142 (34.6)
Heater probe 17 (4.1%)
Heater probe + epinephrine 7 (1.7%)
Outcome
Rebleeding 77 (9.7)
30-day mortality 41 (5.2)
Blood transfusion 394 (49.5)
Surgery 47 (5.9)
Median hospital stay (days, range) 6 (0-45)
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Fig. 3. Univariate and multivariate factors infl uencing 
mortality in 796 patients with bleeding peptic ulcer. 
Fig. 2. Univariate and multivariate factors infl uencing 
rebleeding in 796 patients with bleeding peptic ulcer.
ic hemostasis, 1 due to perforation during the proce-
dure, and 41 due to recurrent bleeding). Most of the 
transferred patients had bleeding from the posterior 
wall of the duodenum, posterior proximal third of the 
gastric corpus, and from the small gastric curvature. 
Th e most common surgical procedure performed was 
mechanical hemostasis (ligation) and gastric resection. 
Th e total 30-day mortality was 5.2%. Th e risk of lethal 
outcome was increased in patients with shock [OR 
2.74 (CI 95% 1.19-6.33)], recurrent bleeding [OR 
3.54 (CI 95% 1.59-7.88)], ulcers >2 cm in diameter 
[OR 3.08 (CI 95% 1.50-6.33)] and moderate to severe 
comorbidities (ASA ≥3) [OR 6.32 (CI 95% 2.38-
16.7)] (Fig. 3).
Only 1/10 patients died from bleeding out and half 
of them were treated with red blood cell transfusions. 
Th e median volume of red blood cell transfusion was 
2.2 (1-6) units and the median hospital stay was 6 (1-
45) days (Table 2).
Discussion
Th ere has been a signifi cant decline in the inci-
dence of PUB and its complications since the intro-
duction of PPIs and H. pylori eradication therapy. A 
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lower incidence was observed in Sweden from 1987 to 
2004 in both men and women, and one study conduct-
ed in the Netherlands found a decline from 61/100,000 
to 48/100,000 per year from 1993 to 200017. In Ger-
many and the United Kingdom, the incidence of PUB 
has remained unchanged, but the average patient age 
has increased18,19. In the Zagreb County, Croatia, the 
incidence of UGIB and PUB did not signifi cantly 
change from 2008 to 2012. Th is can be explained by 
the lower prevalence of H. pylori infection and in-
creased use of drugs that aff ect the cytoprotective 
function of gastric mucosa (NSAIDs and acetylsali-
cylic acid), which has also been shown in other stud-
ies20. Th e average patient age in this study was higher 
than 65 years. In one study, Van Leerdam found that 
70% of patients with UGIB were older than 60 years 
and 40% had several life-threatening diseases4, and in 
another one Van Leerdam et al. report that about 50% 
of patients with PUB were taking NSAIDs and ace-
tylsalicylic acid, with only 12% of them taking PPI as 
protection17. H. pylori infection was diagnosed in 40% 
of patients and was found more frequently in patients 
with bleeding duodenal ulcers. In one prospective 
study conducted in the Netherlands, H. pylori testing 
was performed in 65% of patients with 43% having 
positive fi ndings, while a German study found that 
56% of patients with PUB were H. pylori positive18,21. 
Gralnek et al. found that PUB made up 28% to 59% of 
all UGIB. Half of the patients were categorized as 
high-risk ulcer patients (Forrest Ia, Ib, IIa and IIb)22. 
In a study by Bratanic et al., around 30% of patients 
were described as high-risk23. In our study, PUB repre-
sented about 40% of all non-variceal UGIB, and 
bleeding gastric ulcers were found more frequently 
than bleeding duodenal ulcers. Rebleeding after endo-
scopic treatment with endoclips or endoclips/diluted 
epinephrine occurred in 10% of patients and 5.9% of 
them required surgical intervention. Th e risk of recur-
rent bleeding was increased in patients with shock, ac-
tively bleeding ulcers, and ulcers larger than 2 cm in 
diameter. Our results are consistent with the results 
from other tertiary centers, and despite all endoscopic 
methods for hemostasis available, acute recurrent 
hemorrhage is still common, occurring in 10% to 28% 
of cases24,25. We report a total 30-day mortality of 5.2%. 
Only 10% of patients died because of bleeding out, 
while others died from other comorbidities. Mortality 
was increased in patients with shock, recurrent bleed-
ing ulcers larger than 2 cm in diameter, and moderate 
to severe comorbidities (ASA ≥3). Almost 60% of pa-
tients with PUB presented with moderate to severe 
comorbidities (ASA III and IV). When considering 
other studies, Marmo et al. report a PUB mortality rate 
of 4% to 5% in one prospective study26. Van Leerdam 
et al. showed that 40% of patients that died because of 
UIGB had one or several life-threatening comorbidi-
ties17. Marmo et al. showed that in the fi rst 24 hours of 
hospitalization, less than 30% of all patients died26. 
Villauneva et al. compared the effi  cacy of a restrictive 
transfusion strategy (target hemoglobin 7-9 g/dL) 
with that of a liberal transfusion strategy (target he-
moglobin 9-11 g/dL) in patients with acute gastroin-
testinal bleeding, fi nding that the probability of sur-
vival at 6 weeks was higher in the restrictive-strategy 
group27. Th is was also observed in a subgroup analysis 
of patients with PUB. Other authors also suggest bet-
ter patient outcomes when the restrictive red blood 
cell transfusion strategy is used8,28-30. In our study, half 
of the patients received red blood cell transfusions, 
with a median of 2.2 units.
Th e limitations of this study included diverse med-
ical staff  involved in endoscopic evaluation and treat-
ment, resulting in inter-observer variability in endo-
scopic evaluation and treatment. Furthermore, this 
study had a short follow-up period of 30 days and was 
conducted in a tertiary center.
In conclusion, the incidence of UGIB and PUB re-
mained unchanged in the observed period from 2008 to 
2012, but we recorded an increase in the average age of 
PUB patients. Predictors of mortality in patients with 
PUB included shock, recurrent bleeding, ulcers larger 
than 2 cm in diameter, and moderate to severe comor-
bidities. Prevention of PUB, prompt intravascular vol-
ume replacement, early (≤24 hours) upper GI endosco-
py, and a restrictive red blood cell transfusion strategy 
are important in the management of these patients.
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Sažetak
KRVARENJE IZ PEPTIČKOG VRIJEDA – ISKUSTVA TERCIJARNOG CENTRA: 
EPIDEMIOLOGIJA, LIJEČENJE I PROGNOZA
I. Budimir, S. Stojsavljević, D. Hrabar, D. Kralj, A. Bišćanin, L.S. Kirigin, 
M. Zovak, Ž. Babić, S. Bohnec i I. Budimir ml.
Cilj ove studije bio je prikazati epidemiološke, kliničke i endoskopske karakteristike akutnog krvarenja iz gornjeg pro-
bavnog sustava s naglaskom na krvarenje iz peptičkog vrijeda. U studiju je bilo uključeno 2198 bolesnika koji su pregledani 
u hitnoj službi naše ustanove zbog akutnog krvarenja iz gornjeg probavnog sustava u razdoblju od siječnja 2009. do prosinca 
2012. godine. Svim bolesnicima je učinjena hitna gastroskopija unutar 24 sata od prijma, a u 842 bolesnika kod kojih je do-
kazana peptička ulkusna bolest nastavljeno je kliničko praćenje. Kumulativna incidencija krvarenja je bila 126/100.000 u 
razdoblju od 5 godina. Dva od pet bolesnika su imali krvareći peptički vrijed; ukupno 440 (52,3%) bolesnika je imalo krva-
reći želučani vrijed, 356 (42,3%) duodenalni vrijed, 17 (2%) želučani i duodenalni vrijed, a 29 (3,5%) krvareći vrijed na 
 gastroenteralnoj anastomozi. Srednja dob bolesnika je bila 65,9 godina. Većina bolesnika je uzimala lijekove koji suprimiraju 
citoprotektivne funkcije želučane i duodenalne sluznice (57%). Recidiv krvarenja zabilježen je u 77 (9,7%) bolesnika, a 47 
(5,9%) je zahtijevalo kiruršku intervenciju. Smrtnost kroz 30 dana je bila 5,2%, a 10% bolesnika je umrlo zbog krvarenja i 
pratećih komorbiditeta. Krvarenje iz peptičkog vrijeda je najčešći uzrok krvarenja iz gornjeg probavnog sustava, a obilježeno 
je značajnom stopom recidiva krvarenja i smrtnosti.
Ključne riječi: Gastrointestinalno krvarenje – epidemiologija; Gastrointestinalno krvarenje – terapija; Peptički vrijed, krvare-
nje – epidemiologija; Peptički vrijed – terapija; Endoskopija, gastrointestinalna; Prognoza; Tercijarni zdravstveni centri; Hrvatska
